Updating results

1212 results

Sort: Relevance | Date

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12

Technology appraisal guidance Published November 2007

Bortezomib monotherapy for relapsed multiple myeloma (TA129)

Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)

Technology appraisal guidance Published October 2007

Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids

Technology appraisal guidance Published September 2007

Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published August 2007

Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published August 2007

Varenicline for smoking cessation (TA123)

Evidence-based recommendations on varenicline (Champix) to help people stop smoking

Technology appraisal guidance Published July 2007

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

Technology appraisal guidance Published June 2007

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published February 2007

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C

Technology appraisal guidance Published September 2010

Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (TA20)

Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)

Technology appraisal guidance Published January 2001

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

Technology appraisal guidance Published August 2010 Last updated December 2012

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

Technology appraisal guidance Published August 2010

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2010

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published July 2010

Capecitabine for the treatment of advanced gastric cancer (TA191)

Evidence-based recommendation on capecitabine (Xeloda) for treating advanced (inoperable) gastric cancer (stomach cancer)

Technology appraisal guidance Published July 2010

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer

Technology appraisal guidance Published January 2007 Last updated January 2012

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease

Technology appraisal guidance Published January 2007

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Naltrexone for the management of opioid dependence (TA115)

Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence

Technology appraisal guidance Published January 2007

Methadone and buprenorphine for the management of opioid dependence (TA114)

Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence

Technology appraisal guidance Published January 2007

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Laparoscopic surgery for colorectal cancer (TA105)

Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer

Technology appraisal guidance Published August 2006

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults

Technology appraisal guidance Published July 2006

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

Technology appraisal guidance Published June 2006

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer

Technology appraisal guidance Published April 2006

Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)

Evidence-based recommendations on routine antenatal anti-D prophylaxis for women who are rhesus D negative

Technology appraisal guidance Published August 2008

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

Technology appraisal guidance Published August 2008 Last updated May 2012

Telbivudine for the treatment of chronic hepatitis B (TA154)

Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Entecavir for the treatment of chronic hepatitis B (TA153)

Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Drug-eluting stents for the treatment of coronary artery disease (TA152)

Evidence-based recommendations on drug-eluting stents for the treatment of coronary artery disease

Technology appraisal guidance Published July 2008

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck

Technology appraisal guidance Published June 2008

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome

Technology appraisal guidance Published March 2008

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5

Technology appraisal guidance Published August 2000

Guidance on the Extraction of Wisdom Teeth (TA1)

Evidence-based recommendations on the extraction of wisdom teeth

Technology appraisal guidance Published March 2000

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

Technology appraisal guidance Published March 2019

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma

Technology appraisal guidance Published January 2019

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years

Technology appraisal guidance Published December 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in

Technology appraisal guidance Published June 2018

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018